When “subject to regulatory approval” means troubles: forms of government intervention in M&A transactions

Introduction A persistent financial crisis, the rising of regional tensions, the concerns of a trade war and many other facts have recently been catching up with the M&A-friendly international environment. Protectionism seems now to pervade the new world order. Rising economic nationalism is threatening to impact M&A activity across all Read more…

Pfizer sets sail for a new (nearer) shore: Hospira

Pfizer Inc.; market cap (as of 20/02/2015): US$217.75bn Hospira Inc.; market cap (as of 20/02/2015): US$14.97bn Introduction On February 5th, 2014, pharmaceutical behemoth Pfizer signed with Hospira, the world’s leading provider of injectable drugs and biosimilars, a definitive merger agreement which consists of the fully acquisition of Hospira for US$90 Read more…